Medication info
Jadiwon Tablet 10 mg (Empagliflozin)

Jadiwon Tablet 10 mg (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tablet
Manufacturer / importer
Genupharm Co., Ltd.
Appearance
Light yellow round film-coated tablet
Packaging
PTP packaging - 30 tablets/PTP[10 tablets/PTPX3], PTP packaging - 10 tablets/PTP[10 tablets/PTPX1]
Approval status
Active

MFDS item code 202105612 · Approved 2021.07.29 · Insurance code 698004780

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine for monotherapy and as add-on combination therapy with other glucose-lowering agents, including insulin, is 10 mg once daily. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken regardless of food. Swallow the tablet whole. If a dose is missed, take it as soon as remembered. Do not take a double dose in one day. Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Do not initiate treatment with this medicine in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose of this medicine at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those undergoing dialysis, as efficacy is not expected. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as they have not been studied. Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions)

Ingredients

Manufacturer
Genupharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar in adults with type 2 diabetes. It can be administered alone or in combination with other medications as an adjunct to diet and exercise. In particular, for patients whose blood sugar is not adequately controlled and have cardiovascular disease, it is important to refer to expert information due to the risk of cardiovascular events. Overall, this medication helps to improve blood sugar management and prevents complications.

How to take

Adult dose

The recommended dose of this medicine for monotherapy and as add-on combination therapy with other glucose-lowering agents, including insulin, is 10 mg once daily. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken regardless of food. Swallow the tablet whole. If a dose is missed, take it as soon as remembered. Do not take a double dose in one day. Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Do not initiate treatment with this medicine in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose of this medicine at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those undergoing dialysis, as efficacy is not expected. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as they have not been studied. Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions)

Precautions

This medication should not be administered to certain patients. Firstly, individuals who are allergic to any of the components of this medication should not take it. Secondly, patients with type 1 diabetes or diabetic ketoacidosis should not use this medication. Thirdly, individuals with severely impaired renal function or those undergoing dialysis due to end-stage renal disease should not take this medication. Fourthly, patients with lactose intolerance or related genetic disorders should not take this medication due to the lactose it contains. This medication should be used with caution in patients with reduced renal function. If renal function declines below a certain level, the dosage of this medication should be adjusted or it should be discontinued. It is not effective in patients with end-stage renal disease or those undergoing dialysis. In patients with heart failure, this medication should be used cautiously in mild to moderate cases, and it is not recommended for severe heart failure patients. When used together with insulin or insulin secretagogues, there may be a risk of hypoglycemia, so it may be necessary to reduce the dosage of these medications. Possible side effects during the use of this medication include hypoglycemia, genital infections, urinary tract infections, increased urination, and decreased fluid volume. Hypoglycemia, in particular, may occur more frequently when taken with insulin or sulfonylureas. A serious metabolic disturbance called ketoacidosis can rarely occur, so symptoms like vomiting, abdominal pain, lethargy, or difficulty breathing should be reported to medical professionals immediately. Elderly patients or those at risk of fluid loss should be cautious of dehydration or hypotension, and regular monitoring of physical status is essential. This medication may increase the risk of genital fungal infections, so appropriate treatment should be sought if related symptoms arise. It is recommended that this medication not be taken during pregnancy, and breastfeeding should also be discontinued if necessary. Safety and efficacy have not been established for children and adolescents, so it is not used in these populations. No specific toxicity has been reported in case of overdose, but appropriate treatment may be necessary depending on the clinical situation. This medication should be kept out of reach of children, and transferring it to another container should be avoided. There is a risk of hypoglycemia while driving or operating machinery, so caution is required, particularly when taken with insulin. Regular monitoring of renal function and blood sugar levels is important while taking this medication. Additionally, this medication may interact with other drugs, so if you are taking any other medications, you should inform your healthcare provider.

Side effects

  • Hypoglycemia
  • vulvovaginitis
  • balanitism
  • and other genital infections
  • urinary tract infections
  • perineal necrosis
  • ketoacidosis
  • pruritus
  • rash
  • urticaria
Show 12 more
  • angioedema
  • decreased fluid volume
  • increased urination
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a well-sealed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius. This will help to preserve the medication's efficacy and safety for a longer time.

Appearance and packaging

Appearance

Light yellow round film-coated tablet

Package unit

PTP packaging - 30 tablets/PTP[10 tablets/PTPX3], PTP packaging - 10 tablets/PTP[10 tablets/PTPX1]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.